Adaptive Biotechnologies ADPT Service — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's service — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's service — revenue?
- Adaptive Biotechnologies (ADPT) reported service — revenue of $58.09M in Q1 2026.
- How has Adaptive Biotechnologies's service — revenue changed year-over-year?
- Adaptive Biotechnologies's service — revenue increased by 48.1% year-over-year, from $39.22M to $58.09M.
- What is the long-term trend for Adaptive Biotechnologies's service — revenue?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's service — revenue has grown at a 36.1% compound annual growth rate (CAGR), from $56.21M to $192.83M.
- What does service — revenue mean?
- This metric represents the total gross revenue generated from the company's service-based offerings, specifically excluding any assessed taxes collected from customers. It serves as a primary indicator of the commercial adoption and market demand for the company's clinical diagnostic and immune-monitoring services. Growth in this figure reflects the successful scaling of service-based business models and the ongoing utilization of proprietary diagnostic platforms by healthcare providers and research partners.